Portal de Periódicos da CAPES

Next-Generation Nanomedicines and Nanosimilars: EU Regulators’ Initiatives Relating to The Development and Evaluation of Nanomedicines

2013; Future Medicine; Volume: 8; Issue: 5 Linguagem: Inglês

10.2217/nnm.13.68

1748-6963

Falk Ehmann, Kumiko Sakai‐Kato, Ruth Duncan, Dolores Hernán Pérez de la Ossa, Ruben Pita, Jean-Marc Vidal, Ashish Kohli, László Tóthfalusi, Alan Sanh, Sandrine A. Tinton, Jean-Louis Robert, Beatriz Silva Lima, M. Papaluca Amati,

Graphene and Nanomaterials Applications

Over the last three decades many first-generation nanomedicines have successfully entered routine clinical use and it is now important for medicines regulatory agencies to consider the mechanisms needed to ensure safe introduction of 'follow-on' nanomedicine products, 'nanosimilars'. Moreover, drug regulators need to ensure that 'next'-generation nanomedicines enter clinical development and consequently the market in a safe and timely way for the benefit of public health. Here we review recent European Medicines Agency activities that relate to the effective development and evaluation of nanomedicine products while keeping patient and consumer safety at the forefront.